Methyl 2-Cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me)
Decreases Specificity Protein (Sp) Transcription Factors
and Inhibits Pancreatic Tumor Growth: Role of MicroRNA-27a

Indira Jutooru*, Gayathri Chadalapaka*, Maen Abdelrahim, Md Riyaz Basha,
Ismael Samudio, Marina Konopleva, Michael Andreeff, and Stephen Safe

Department of Veterinary Physiology and Pharmacology
Texas A&M University
4466 TAMU
College Station, TX 77843
(IJ, GC, SS)

Cancer Research Institute
M.D. Anderson Cancer Center
1100 Bonnie Loch Ct.
Orlando, FL 32806
(MA, MRB)

Section of Molecular Hematology and Therapy
Department of Stem Cell Transplantation and Cellular Therapy
M.D. Anderson Cancer Center
Houston, TX 77030
(IS, MK, MA)

Institute of Biosciences and Technology
Texas A&M Health Science Center
2121 Holcombe Blvd.
Houston, TX 77030
(SS)
Running Title: CDDO-Me downregulates Sp proteins via ROS-initiated pathway

All correspondence should be sent to:
Stephen Safe
Department of Veterinary Physiology and Pharmacology
Texas A&M University
4466 TAMU, Vet. Res. Bldg. 410
College Station, TX 77843-4466
Tel: 979-845-5988 / Fax: 979-862-4929
Email: ssafe@cvm.tamu.edu

Text pages: 38
Tables: 0
Figures: 7
Supplemental Figures: 3
References: 42

Number of words
  Abstract: 248
  Introduction: 564
  Discussion: 1606

Abbreviations:
CDDO, 2-cyano-3,12-dioxoleana-1,9-dien-28-oic acid; CDDO-IM, imidazole ester of CDDO; CDDO-Me, methyl ester of CDDO; CDODA, 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oic acid; CDODA-Me, methyl ester of CDODA; ER, endoplasmic reticulum; GSH, glutathione; MMP, mitochondrial membrane potential; PPARγ, peroxisome proliferator-activated receptor γ; ROS, reactive oxygen species; Sp, specificity protein; VEGF, vascular endothelial growth factor
ABSTRACT

The anticancer agent 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its methyl ester (CDDO-Me) typically induce a broad spectrum of growth inhibitory, proapoptotic and antiangiogenic responses. Treatment of Panc1, Panc28 and L3.6pL pancreatic cancer cells with low μM concentrations of CDDO or CDDO-Me resulted in growth inhibition, induction of apoptosis, and downregulation of cyclin D1, survivin, vascular endothelial growth factor (VEGF) and its receptor (VEGFR2). RNA interference studies indicate that these repressed genes are regulated by specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4, and western blot analysis of lysates from pancreatic cancer cells treated with CDDO and CDDO-Me shows for the first time that both compounds decreased expression of Sp1, Sp3 and Sp4. Moreover, CDDO-Me (7.5 mg/kg/day) also inhibited pancreatic human L3.6pL tumor growth and downregulated Sp1, Sp3 and Sp4 in tumors using an orthotopic pancreatic cancer model. CDDO-Me also induced reactive oxygen species (ROS) and decreased mitochondrial membrane potential (MMP) in Panc1 and L3.6pL cells, and cotreatment with antioxidants (glutathione and dithiothreitol) blocked formation of ROS, reversed the loss of MMP, and also inhibited downregulation of Sp1, Sp3 and Sp4. Repression of Sp and Sp-dependent genes by CDDO-Me was due to downregulation of microRNA-27a and induction of ZBTB10, an Sp repressor, and these responses were also reversed by antioxidants. Thus, the anticancer activity of CDDO-Me is due, in part, to activation of ROS which in turn targets the microRNA-27a:ZBTB10-Sp transcription factor axis. This results in decreased expression of Sp-regulated genes, growth inhibition, induction of apoptosis, and antiangiogenic responses.
INTRODUCTION

Extracts of plants and microorganisms and individual natural products have been extensively used as traditional medicines for treatment of several diseases including cancer. Individual natural products including aspirin, morphine, quinine, statins, penicillins, taxanes and many other compounds are widely used pharmaceutical agents and also serve as templates for the synthesis of more potent analogs (Koehn and Carter, 2005). Triterpenoid are derived from cyclization of oxidosqualene, and different cyclization pathways coupled with post-cyclization modifications can give several thousand possible analogs including oleanolic acid which contains a pentacyclic oleanane skeleton and a C28 carboxyl group. Oleanolic acid has been used by Sporn, Honda and their collaborators as a template for extensive structure-activity studies to identify antiinflammatory drugs, and the most active compounds identified were 2-cyano-3,12-dioxoleana-1,9-dien-28-oic acid (CDDO) and its corresponding methyl (CDDO-Me) and imidazole (CDDO-Im) esters (Honda et al., 1998; Honda et al., 2000; Liby et al., 2007).

The anticancer activities of CDDO and related compounds have been extensively investigated in several different cancer cell lines and in vivo and their remarkable potency is due to modulation of several important pathways [reviewed in (Liby et al., 2007)]. Initial studies showed that CDDO was a peroxisome proliferator-activated receptor γ (PPARγ) agonist (Wang et al., 2000); however, most subsequent studies indicate that the anticancer activities of CDDO and related compounds were PPARγ-independent (Melichar et al., 2004; Ray et al., 2006). The effects of CDDO, CDDO-Me...
and CDDO-Im vary among different cell lines and are dependent on the specific parameters measured; however, treatment with these compounds invariably resulted in growth inhibition, antiangiogenic activity and induction of apoptosis (Liby et al., 2007). Induction of these responses is associated with modulation of several pathways and genes including activation of endoplasmic reticulum (ER) stress, microtubule disruption, direct binding to specific thiol groups in proteins, inhibition of NFκB signaling, and mitochondriotoxicity, resulting in decreased mitochondrial membrane potential (MMP) (Ikeda et al., 2003; Ikeda et al., 2004; Liby et al., 2007; Samudio et al., 2005; Samudio et al., 2006; Yore et al., 2006; Yue et al., 2006). For example, in pancreatic cancer cells, CDDO-Im inhibits cell growth and induces apoptosis and this is associated with decreased MMP and mitochondrial glutathione (GSH) and induction of reactive oxygen species (ROS) (Samudio et al., 2005).

Studies in this laboratory have characterized the anticancer activity of 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oic acid (CDODA) and its methyl ester (CDODA-Me) which are structurally similar to CDDO and CDDO-Me but are derived from the triterpenoid glycyrrhetinic acid, a bioactive component of licorice (Chadalapaka et al., 2008b; Chintharlapalli et al., 2007a; Chintharlapalli et al., 2009; Jutooru et al., 2009; Papineni et al., 2008). A recent study reported that one of the underlying mechanism of action of CDODA-Me in colon cancer cells was due to downregulation of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4 and Sp-dependent genes (Chintharlapalli et al., 2009). In this study, we demonstrate for the first time that CDDO and CDDO-Me also decrease expression of Sp1, Sp3 and Sp4 and Sp-dependent gene products (VEGF, cyclin D1, survivin and VEGFR2) in pancreatic cancer cells and
tumors in an orthotopic mouse model. The mitochondriotoxicity of CDDO-Me results in decreased MMP, induction of ROS, ROS-dependent downregulation of microRNA-27a, and induction of ZBTB10 (an Sp repressor protein) which in turn downregulates Sp transcription factors and Sp-dependent genes. Thus, CDDO-Me-dependent repression of Sp1, Sp3 and Sp4 contributes to the potent anticancer activity of CDDO and related compounds.
MATERIALS AND METHODS

Cell Lines. Panc28 cell line was a generous gift from Dr. Paul Chiao and L3.6pL cells were kindly provided by Dr. Isaiah Fidler (University of Texas M.D. Anderson Cancer Center, Houston, TX) and Panc1 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). The HPDE immortalized pancreatic cell line was kindly provided by Dr. M-T. Tsao (Ontario Cancer Institute, Toronto, Canada).

Antibodies and Reagents. All three pancreatic cancer cell lines were maintained in DMEM-F12 supplemented with 5% FBS, 0.22% sodium bicarbonate, and 10 mL/L of 100X antibiotic/antimycotic cocktail solution (Sigma-Aldrich Co., St. Louis, MO). Cells were grown in 150 cm² culture plates in an air/CO₂ (95:5) atmosphere at 37°C. Cyclin D1, Sp3, Sp4, VEGF and VEGFR2 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Cleaved PARP antibody was purchased from Cell Signaling Technology (Danvers, MA) and Sp1 antibody was purchased from Millipore (Billerica, MA). Survivin antibody was purchased from R&D systems (Minneapolis, MN). Monoclonal β-actin antibody was purchased from Sigma-Aldrich. Horseradish peroxidase substrate for western blot analysis was obtained from Millipore. Dithiothreitol and γ-L-glutamyl-L-cysteinyl-glycine (GSH) were obtained from Sigma-Aldrich. Superscript II, LipofectAMINE and LipofectAMINE 2000 was purchased from Invitrogen (Carlsbad, CA). Reporter lysis buffer and luciferase reagent were purchased from Promega (Madison, WI). β-Galactosidase reagent was obtained from Tropix (Bedford, MA). Primers for TBP and ZBTB10 were purchased from Integrated DNA Technologies Technologies (Coralville, IA). Primers for Sp3 and Sp4 were obtained from Qiagen (Valencia, CA); ZBTB10 expression vector and empty vector (pCMV6-XL4)
were from Origene (Rockville, MD). MiRNA mirRNA extraction kits and the reverse transcription (RT) and real-time PCR amplification kits were purchased from Applied Biosystems (Foster City, CA). The VEGF and survivin promoter constructs were provided by Drs. Gerhard Siemista and Gunter Finkenzeller (Institute of Molecular Medicine, Tumor Biology Center, Freiburg, Germany) and Dr. M. Zhou (Emory University, Atlanta, GA). Sp1 and Sp3 promoter constructs were kindly provided by Drs. Carlos Cuidad and Veronique Noe (University of Barcelona, Barcelona, Spain).

**Cell Proliferation Assay.** Pancreatic cancer cells (3×10⁴ per well) were plated in 12-well plates and allowed to attach for 24 hr. The medium was then changed to DMEM/Ham’s F-12 medium containing 2.5% charcoal-stripped FBS, and either vehicle (DMSO) or different doses of CDDO or CDDO-Me were added. Cells were trypsinized and counted every 48 hr using a Coulter Z1 particle counter for 6 days. Fresh medium and test compounds were added every 48 hr. Each experiment was done in triplicate and results are expressed as means ± SE for each treatment group.

**Transfection and Luciferase Assay.** Pancreatic cancer cells (1×10⁵ per well) were plated in 12-well plates in DMEM/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped FBS. After 24 hr, various amounts of DNA [i.e., 0.4 μg PGL2-Luc, 0.4 μg PGL3-Luc, 0.04 μg β-galactosidase, and 0.4 μg pSp1 (4)-Luc or 0.4 μg pSp3-Luc or 0.4 μg VEGF (2068)-Luc or 0.4 μg pSurvivin (269)-Luc] were transfected using Lipofectamine reagent according to the manufacturer’s protocol. Five hr posttransfection, the transfection mix was replaced with complete medium containing either vehicle (DMSO) or the indicated compound in DMSO. After 22 hr, cells were then lysed with 100 μL of 1X reporter lysis buffer, and cell extracts (30 mL) were used for
luciferase and β-galactosidase assays. A Lumicount luminometer was used to quantitate luciferase and β-galactosidase activities, and the luciferase activities were normalized to β-galactosidase activity.

**Transfection With Antisense miR-27a (as-miR-27a), Small Inhibitory RNAs Against Sp1, Sp3 and Sp4, and ZBTB10 Expression Vector.** Pancreatic cancer cells (1x10^5 per well) were plated in 12-well plates in DMEM/Ham’s F-12 medium supplemented with 2.5% charcoal-stripped FBS. After 24 hr, cells were transfected with empty vector (pCMV6-XL4) or 4 μg/well ZBTB10 expression plasmid pCMV6-XL4 vector using Lipofectamine 2000 reagent according to the manufacturer’s protocol. After transfection for 5 hr, the transfection mix was replaced with complete medium and incubated for 48 hr. A similar approach was used in studies with as-miR-27a to determine its effect on cell proliferation and apoptosis. Small inhibitory RNAs for Sp1 (iSp1), Sp3 (iSp3), Sp4 (iSp4), and their combination (iSp1/3/4) were also transfected into Panc1 and L3.6pL cells, and inhibition of cell proliferation and induction of PARP cleavage were determined after 72 hr. The oligonucleotides used for this study have previously been described (Chadalapaka et al., 2008a; Chadalapaka et al., 2010).

**Western Blots.** Pancreatic cancer cells (3x10^5 per well) were seeded in 6-well plates in DMEM/Ham’s F-12 medium containing 2.5% charcoal-stripped FBS and after 24 hr, cells were treated with either vehicle (DMSO) or the indicated compounds. Cells were collected using high-salt buffer [50 mmol/L HEPES, 0.5 mol/L NaCl, 1.5 mmol/L MgCl₂, 1 mmol/L EGTA, 10% glycerol, and 1% Triton-X-100] and 10 μL/mL of Protease Inhibitor Cocktail (Sigma-Aldrich). Protein lysates were incubated for 3 min at 100°C before electrophoresis, and then separated on 10% SDS–PAGE 120 V for 3 to 4 hr.
Proteins were transferred onto polyvinylidene difluoride (PVDF) membranes by wet electroblotting in a buffer containing 25 mmol/L Tris, 192 mmol/L glycine, and 20% methanol for 1.5 hr at 180 mA. Membranes were blocked for 30 min with 5% TBST-Blotto [10 mmol/L Tris-HCl, 150 mmol/L NaCl (pH 8.0), 0.05% Triton X-100, and 5% nonfat dry milk] and incubated in fresh 5% TBST-Blotto with 1:500 primary antibody overnight with gentle shaking at 4°C. After washing with TBST for 10 min, the PVDF membrane was incubated with secondary antibody (1:5000) in 5% TBST-Blotto for 2 hr by gentle shaking. The membrane was washed with TBST for 10 min, incubated with 6 mL of chemiluminescence substrate for 1 min, and exposed to Kodak image station 4000 mm Pro (Carestreamhealth, Woodbridge, Connecticut).

**Animals and Orthotopic Implantation of Tumor Cells.** Male athymic nude mice (NCI-nu) were purchased from the Animal Production Area of the National Cancer Institute Frederick Cancer Research and Development Center (Frederick, MD). Mice were housed and maintained under specific pathogen-free conditions in facilities approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the United States Department of Agriculture, United States Department of Health and Human Services, and the National Institutes of Health. Mice with 8-12 wk of age were used for the current study. L3.6pL cells were harvested from subconfluent cultures by a brief exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization was stopped with medium containing 10% fetal bovine serum, and the cells were washed once in serum-free medium and resuspended in HBSS. Only suspensions consisting of single cells with >90% viability were used for the injections. Injection of cells into the pancreas was performed as
described previously (Abdelrahim et al., 2006). One week after the injection of the cells, 4-5 mice were randomly selected and sacrificed, and the pancreas was isolated from all the animals and tested under microscope to confirm the initiation of tumor growth. The remaining mice were divided into two groups (at least 5 animals/group) and treated (orally) with vehicle (control) or 7.5 mg/kg CDDO-Me daily for 4 weeks. Animals were sacrificed and the primary pancreatic tumors were isolated. All the tumors were measured and their weights were recorded. The tumor tissues were properly isolated into 3 portions for preparing (1) protein extracts (snap frozen in liquid nitrogen and stored at -80°C); (2) RNA [treated with RNA stabilization solution (RNAlater) and then stored at -80°C]; and (3) paraffin sections for immunohistochemistry (fixed in formaldehyde).

**ROS estimation.** Cellular ROS levels were evaluated with the cell-permeable probe CM-H$_2$DCFDA (5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester) from Invitrogen. Following treatment for 20-24 hr, cells plated on 96-well cell culture plates were loaded with 10 μM CM-H$_2$DCFDA for 30 min, washed once with serum free medium, and analyzed for ROS levels using the BioTek Synergy 4 plate reader (Winooski, VT) set at 480 nm and 525 nm excitation and emission wavelengths, respectively. Following reading of ROS, cultures were then treated with Janus green and cell counts were determined with the plate reader set to an absorbance of 610 nm, and ROS intensities were then corrected accordingly. Each experiment was done in triplicate and results are expressed as means ± SE for each treatment group.

**Measurement of Mitochondrial Membrane Potential (MMP).** MMP was measured with Mitochondrial Membrane Potential Detection Kit (Stratagene Cedar...
Creek, TX) according to manufacturer’s protocol using JC-1 dye. Pancreatic cancer cells were plated on 2-well Lab-Tex Coverglass slides (NUNC, NY) and, after 24 hr, cells were treated with DMSO or CDDO-Me alone or with GSH for 16 hr. Cells were then incubated with 1X JC-1 dye at 37°C for 15 min and washed twice with assay buffer according to manufacturer’s protocol and then cells were subjected to microscopic analysis using Zeiss Stallion Dual Detector Imaging System (Carl Zeiss Microimaging Inc., Thornwood, NY) using a C-Apochromat 63X, 1.2 NA water immersion lens. J-aggregates are detected as red fluorescence and J-monomers are detected as green fluorescence. The ratio of red fluorescence to green fluorescence was measured using Image J Software. Cells were examined in more than ten fields per slide on multiple slides. Data represent the average of all the fields.

**Quantitative Real-time PCR of mRNA and miRNA.** cDNA was prepared from Panc1 and L3.6pL cell lines using Superscript II reverse transcriptase (Invitrogen) according to manufacturer’s protocol. Each polymerase chain reaction (PCR) was carried out in triplicate in a 20-μl volume using SYBR GreenER (Invitrogen) for of 95°C for 10 min, then 40 cycles of 95°C for 15 s and 60°C for 1 min in the Applied Biosystems 7500 Fast Real-time PCR System. The following primers were used.

- **TBP (F):** 5'-TGCACAGGAGCCAAGAGTGAA-3' 
- **TBP (R):** 5'-CACATCACAGCTCCCCACCA-3' 
- **ZBTB10 (F):** 5'-GCTGGATAGTAGTTATGTTGC-3' 
- **ZBTB10 (R):** 5'-CTGAGTGGTTTGATGGACAGA-3' 

mirVana miRNA extraction kit (Applied Biosystems) was used for extraction of miRNA according to manufacturer’s protocol. Quantification of miRNA (RNU6B and miRNA-
27a) was done using the Taqman miRNA kit (Applied Biosystems) according to the manufacturer's protocol with real-time PCR. U6 small nuclear RNA was used as a control to determine relative miRNA expression.

**Statistical Analysis.** Statistical significance of differences between the treatment groups was determined by an analysis of variance and/or Student’s t-test, and levels of probability were noted. IC\textsubscript{50} values were calculated using linear regression analysis and expressed in \( \mu \text{M} \), at 95% confidence intervals.
RESULTS

The synthetic oleanolic acid derivatives CDDO, CDDO-Me and CDDO-Im are cytotoxic to several different cancer cell lines and the latter derivative was a potent inhibitor of pancreatic cancer cell proliferation (Samudio et al., 2005). In this study, we initially compared the effects of CDDO and CDDO-Me on proliferation of Panc1, Panc28 and L3.6pL pancreatic cancer cell lines for up to 144 hr (Figs. 1A and 1B). IC_{50} values for growth inhibition by CDDO-Me and CDDO after treatment for 48 hr were 5.2 and 0.37 (Panc1), 5.3 and 0.37 (Panc28), and 3.0 and 0.4 µM (L3.6pL), respectively. CDDO-Me was more active than CDDO in all three pancreatic cancer cell lines and there were minimal differences between cell lines to the cytotoxic effects of both compounds. Supplemental Figure 1 show that CDDO-Me also inhibits growth of non-transformed HPDE pancreatic cells; however, this cell line was more resistant to the effects of CDDO-Me than pancreatic cancer cell lines. After prolonged treatment (144 hr) with CDDO-Me and CDDO, IC_{50} values were 0.25 and 1.8 (Panc1), 0.30 and 2.3 (Panc28), and 0.28 and 1.4 µM (L3.6pL), respectively, and the relative potencies of both compounds and cellular responsiveness were similar to that observed after 48 hr. Inhibition of Panc1, Panc28 and L3.6pL cell growth by CDDO and CDDO-Me was also accompanied by apoptosis, and Figures 1C and 1D show that both compounds induced caspase-dependent PARP cleavage in the pancreatic cancer cell lines.

CDDO and related compounds inhibit growth, induce apoptosis, and exhibit antiangiogenic activity in cancer cells derived from multiple tumor types [reviewed in (Liby et al., 2007)], and the effects of CDDO-Me and CDDO on expression of prototypical gene products representing these activities were investigated in the three
pancreatic cancer cell lines. Results in Figure 2A show that 0 - 1.25 μM CDDO-Me and 0 - 5 μM CDDO decrease expression of cyclin D1, survivin, VEGF and VEGFR2 proteins in Panc1 cells. Moreover, similar results were observed in Panc28 (Fig. 2B) and L3.6pL (Fig. 2C) cells, and results in Figures 1 and 2 are consistent with previous studies on CDDO and related compounds in cancer cells (Honda et al., 1998; Honda et al., 2000; Ikeda et al., 2003; Ikeda et al., 2004; Liby et al., 2007; Melichar et al., 2004; Ray et al., 2006; Samudio et al., 2005; Samudio et al., 2006; Wang et al., 2000; Yore et al., 2006).

Knockdown of Sp1, Sp3 and Sp4 transcription factors by RNA interference in pancreatic cancer cells showed that VEGF, VEGFR1 and VEGFR2 expression were regulated by Sp1, Sp3 and Sp4 (Abdelrahim et al., 2004; Abdelrahim et al., 2006; Higgins et al., 2006), suggesting that an underlying mechanism of action of CDDO and CDDO-Me may involve downregulation of Sp proteins as previously described for other bioactive triterpenoids in cancer cells (Chintharlapalli et al., 2007b; Chintharlapalli et al., 2009). Results in Figure 3A demonstrate that 0 - 1.25 μM CDDO-Me and 0 - 5.0 μM CDDO decreased expression of Sp1, Sp3 and Sp4 proteins in Panc1 cells and similar results were observed in Panc28 (Fig. 3B) and L3.6pL (Fig. 3C) cells. The observed CDDO-/CDDO-Me-dependent downregulation of Sp transcription factors (Figs. 3A - 3C) is consistent with their parallel decrease in Sp-dependent genes as illustrated in Figure 2. Previous studies show that the NSAID tolfenamic acid induced proteasome-dependent downregulation of Sp1, Sp3 and Sp4 in Panc1 cells that was blocked by the proteasome inhibitor MG132 (Abdelrahim et al., 2006); however, results in Figure 3D using CDDO-Me, indicate that downregulation of Sp1, Sp3 and Sp4 by this compound
in pancreatic cancer cells was not blocked by the proteasome inhibitor MG132, indicating a proteasome-independent pathway. The proximal regions of the Sp1, Sp3, VEGF and survivin promoters are GC-rich and the effects of CDDO-Me and CDDO on promoter activity were investigated in Panc1 cells transfected with pSp1For4, pSp3For5, pVEGF and pSurvivn constructs which contain -751 to -20 (Sp1), -417 to -38 (Sp3), -2018 to +50 (VEGF), and -269 to +49 (survivin) promoter inserts, respectively. CDDO and CDDO-Me significantly decreased luciferase (reporter gene) activity in Panc1 cells transfected with these constructs (Supplemental Fig. 2) indicating that CDDO and CDDO-Me act at the transcriptional levels and this is consistent with the observed proteasome-independent downregulation results shown in Figure 3D. We also observed that CDDO-Me decreased Sp1 mRNA levels (Supplemental Fig. 3) which is consistent with the inhibitory effects of this compound on transcription.

Previous reports showed that the imidazole derivative of CDDO was mitochondriotoxic in pancreatic cancer cells and this was characterized by decreased MMP and accompanied by induction of ROS (Samudio et al., 2005). Treatment of Panc1 or L3.6pL cells with CDDO-Me also increased total ROS levels as determined by CM-H$_2$DCFDA fluorescent dye and this response was also attenuated after cotreatment with the antioxidant glutathione (Fig. 4A). Panc1 and L3.6pL cells were incubated with the fluorescent dye JC-1 and after treatment with DMSO or GSH, the typical orange/red fluorescent staining of mitochondria was observed (Figs. 4A). However, in Panc1 or L3.6pL cells treated with 1.25 or 1.0 μM CDDO-Me, respectively, there was a significant decrease in orange/red staining and an increase in green fluorescence indicative of decreased MMP and this response was attenuated after cotreatment with GSH in both
cell lines (Fig. 4B). These results demonstrate that CDDO-Me was mitochondriotoxic in pancreatic cancer cells and we therefore investigated the possible connection between CDDO-Me-induced ROS and mitochondrial effects and CDDO-Me-dependent downregulation of Sp1, Sp3 and Sp4 proteins. Results in Figure 4C demonstrate that Sp1, Sp3 and Sp4 are downregulated in Panc1 and L3.6pL cells after treatment with CDDO-Me and decreased expression of Sp1, Sp3 and Sp4 proteins was inhibited after cotreatment with thiol antioxidants (DTT and/or GSH) and similar results were observed in Panc28 cells (data not shown). Hydrogen peroxide or \( t \)-butyl hydroperoxide were used as prototypical model ROS and both compounds decreased expression of Sp1, Sp3 and Sp4 proteins (data not shown), confirming that induction of ROS in pancreatic cancer cells is a critical upstream response in targeting repression of Sp transcription factors, and comparable results have been observed in other cancer cell lines.

CDODA-Me, a triterpenoid structurally-related to CDDO-Me, decreased Sp proteins in colon cancer cells through downregulation of microRNA-27a (miR-27a) and induction of ZBTB10, a zinc finger Sp-repressor protein (Chintharlapalli et al., 2009). After treatment of Panc1 and L3.6pL cells with CDDO-Me, there was a decrease in expression of miR-27a (Fig. 5A) and this was accompanied by increased ZBTB10 mRNA levels (Fig. 5B). Since ZBTB10 suppresses expression of Sp-regulated genes through competitive interactions with GC-rich promoter elements (Chintharlapalli et al., 2009; Mertens-Talcott et al., 2007; Tillotson, 1999), we investigated the effects of ZBTB10 overexpression in Panc1 and L3.6pL cells (Fig. 5C). Overexpression of ZBTB10 in pancreatic cancer cells decreased expression of Sp1, Sp3 and Sp4 proteins and similar results have previously been observed in breast and colon cancer cells.
(Chintharlapalli et al., 2009; Mertens-Talcott et al., 2007). CDDO-Me-dependent induction of ROS and downregulation of Sp proteins is inhibited after cotreatment with antioxidants (Fig. 4) and, therefore, we investigated the role of ROS induction and the effects of antioxidants on expression of ZBTB10 and miR-27a. CDDO-Me decreased miR-27a and induced ZBTB10 in Panc1 and L3.6pL cells and, in cells cotreated with CDDO-Me plus glutathione, these responses were significantly reversed (Fig. 5D). This demonstrates that CDDO-Me-induced ROS is a common upstream factor regulating disruption of miR-27a:ZBTB10–Sp axis.

We also investigated the comparative effects of as-miR-27a, ZBTB10 overexpression, and knockdown of Sp1, Sp3 and Sp4 alone or in combination as previously described (Chadalapaka et al., 2008a; Chadalapaka et al., 2010) on growth inhibition and induction of PARP cleavage in Panc1 and L3.6pL cells (Fig. 6). Transfection of cells with as-miR-27a inhibited growth of Panc1 and L3.6pL cell growth (Fig. 6B) and the results were similar to that observed for as-miR-27a; however, overexpression of ZBTB10 was more potent than as-miR-27a as an inducer of PARP cleavage. Since both as-miR-27a and ZBTB10 are involved in downregulation of Sp1, Sp3 and Sp4 (Fig. 5C) (Mertens-Talcott et al., 2007), the effects of individual Sp knockdown (iSp1, iSp3 and iSp4) or combined knockdown (iSp1/3/4) by RNA interference on cell growth and PARP cleavage were investigated (Figs. 6C and 6D). Panc1 and L3.6pL cell growth was decreased in cells transfected with iSp1/3/4 and the effects of individual Sp knockdown were variable and cell context-dependent; however, loss of Sp1 resulted in the most pronounced growth inhibition in both cell lines. In Panc1 cells, iSp1, iSp3, iSp4 and iSp1/3/4 induced PARP cleavage; however, iSp3 was
the most effective (Fig. 6C), whereas iSp4 and iSp1/3/4 induced PARP cleavage in L3.6pL cells (Fig. 6D). These results demonstrate that the growth inhibitory and proapoptotic effects of CDDO-Me are also observed in pancreatic cancer cells transfected with as-miR-27a or ZBTB10 overexpression or after knockdown of Sp transcription factors.

The in vivo anticancer activity of CDDO-Me was also investigated in an orthotopic model of pancreatic cancer in which L3.6pL cells were injected directly into the pancreas of 8 - 12 week old male thymic nude mice (Abdelrahim et al., 2006; Baker et al., 2002). Treatment with CDDO-Me (7.5 mg/kg daily by oral administration) was initiated 7 days after injection of the cells and continued for an additional 28 days. Treatment with CDDO-Me significantly decreased pancreatic tumor volume and weight (Figs. 7A and 7B) compared to the vehicle control group. In addition, lysate from tumors treated with the vehicle or CDDO-Me (from 3 different animals/group) were also analyzed by western blots and there was a marked decrease in expression of Sp1, Sp3 and Sp4 proteins in tumors from mice treated with CDDO-Me compared to the control group (Fig. 7C). Moreover, we also observed decreased expression of VEGF, cyclin D1 and survivin in tumors from CDDO-Me-treated mice compared to animals receiving vehicle control (Fig. 7D). Body and organ weight changes and evidence for toxicity was not observed (data not shown) and this is consistent with the applications of CDDO compounds in chemoprevention studies (Liby et al., 2007) These in vivo results are consistent with cell culture studies (Figs. 2 and 3) demonstrating for the first time that CDDO-Me represses expression of Sp1, Sp3 and Sp4 transcription factors and Sp-
dependent gene products, suggesting that this hitherto unrecognized pathway also contributes to the anticancer activity of CDDO-Me and related compounds.
DISCUSSION

Sp1 was the first transcription factor identified and is a member of the Sp/Krüppel-like family of zinc finger transcription factors that exhibit a broad range of tissue-specific and overlapping functions (Bouwman and Philipsen, 2002; Safe and Abdelrahim, 2005). Although Sp transcription factors are important during embryonic development, there is evidence that in humans and laboratory animals of a marked decrease in Sp1 with aging (Ammendola et al., 1992; Oh et al., 2007) and studies in this laboratory show that Sp1, Sp3 and Sp4 levels in non-tumor tissue of mice are minimal to non-detectable (Abdelrahim et al., 2006; Abdelrahim et al., 2007; Chintharlapalli et al., 2007b). Several reports show that Sp1 protein is overexpressed in different human tumor types including gastric, colorectal, pancreatic, epidermal, thyroid and breast cancers (Chiefari et al., 2002; Hosoi et al., 2004; Jiang et al., 2008; Mertens-Talcott et al., 2007; Shi et al., 2001; Wang et al., 2003; Yao et al., 2004; Zannetti et al., 2000). In gastric cancer patients, there was an association between Sp1 expression with advanced stage of the tumor, VEGF expression, and poor survival (Yao et al., 2004). Although the mechanism of Sp overexpression has not been determined, Lou and coworkers (Lou et al., 2005) have shown that malignant transformation of human fibroblasts resulted in an 8- to 18-fold increase in Sp1 expression and the transformed cells formed tumors in athymic nude mouse xenografts. In contrast, these transformed cells were not tumorigenic after knockdown of Sp1. Sp1 is overexpressed in pancreatic cancer cells (Shi et al., 2001) and there is a correlation between expression of Sp1 and the angiogenic factor VEGF. Moreover, it was recently reported that Sp1 was a biomarker that identifies patients with a highly aggressive sub-type of pancreatic ductal...
adenocarcinomas (Jiang et al., 2008). Studies in this laboratory show that Sp1, Sp3 and Sp4 are overexpressed in pancreatic and other cancer lines and knockdown of Sp1, Sp3 and Sp4 by RNA interference indicates that expression of several growth-promoting, pro-survival and angiogenic genes/responses are regulated by these transcription factors (Abdelrahim et al., 2004; Abdelrahim et al., 2006; Chadalapaka et al., 2008a; Chintharlapalli et al., 2007b; Mertens-Talcott et al., 2007).

The high expression of Sp1, Sp3 and Sp4 proteins in cancer cells and tumors coupled with their regulation of several critical pro-oncogenic genes suggests that these transcription factors are potentially important drug targets. The non-steroidal antiinflammatory drug tolfenamic acid, the triterpenoid betulinic acid, curcumin and CDDO-Me have previously been characterized as agents that inhibit cancer cell and tumor growth in rodent models and induce downregulation of Sp1, Sp3 and Sp4 through proteasome-dependent and -independent pathways (Abdelrahim et al., 2006; Chadalapaka et al., 2008a; Chintharlapalli et al., 2007b; Chintharlapalli et al., 2009). CDDO/CDDO-Me and CDDA/CDODA-Me activate PPARγ and exhibit some common and also different activities in colon and pancreatic cancer cells (Chintharlapalli et al., 2007a; Wang et al., 2000). A recent study in colon cancer cells showed that CDDO-Me downregulated expression of Sp1, Sp3 and Sp4 and Sp-regulated gene products (Chintharlapalli et al., 2009). Results in Figures 2 and 3 show that CDDO and CDDO-Me also decreased expression of Sp1, Sp3 and Sp4 and Sp-regulated genes such as cyclin D1, VEGF, VEGFR2 and survivin in Panc1, Panc28 and L3.6pL pancreatic cancer cells. Moreover, repression of these gene products by CDDO and CDDO-Me were observed at concentrations that were comparable to those required for inhibition of
Panc1, Panc28 and L3.6pL cell growth and induction of apoptosis (Fig. 1). In contrast to previous reports with tolfenamic acid in pancreatic cancer cells (Abdelrahim et al., 2006; Abdelrahim et al., 2007), CDDO-Me induced proteasome-independent downregulation of Sp1, Sp3 and Sp4 in pancreatic cancer cells (Fig. 3D). CDDO-Me also decreased luciferase activity in cells transfected with constructs containing Sp1, Sp4, VEGF and survivin gene promoter inserts and decreased Sp1 mRNA expression (Supplemental Figs. 2 and 3) which is consistent with the effects of CDDO-Me on transcription. These in vitro cell culture studies confirm the potency of CDDO-Me as an inhibitor of pancreatic cancer cell growth and demonstrate for the first time that the anticancer activity is due, in part, to targeting of Sp transcription factors and Sp-regulated genes. Further evidence for the role of this pathway in the activity of CDDO-Me was observed in an orthotopic model for pancreatic cancer where CDDO-Me (7.5 mg/kg/day) not only inhibited tumor growth but also decreased expression of Sp1, Sp3 and Sp4 proteins in pancreatic tumors (Fig. 7). These results suggest that CDDO-Me activates comparable pathways both in vitro and in vivo and this has previously been observed for other agents that target Sp transcription factors (Abdelrahim et al., 2006; Abdelrahim et al., 2007; Chadalapaka et al., 2008a; Chintharlapalli et al., 2009).

CDDO-Im-dependent anticarcinogenic activity in pancreatic cancer cells has been linked to its mitochondriotoxic activity (Samudio et al., 2005) which was characterized by decreased MMP and GSH and induction of ROS and these responses were blocked in cells cotreated with thiol antioxidants. Not surprisingly, CDDO-Me also induced a similar pattern of mitochondriotoxic responses in pancreatic cancer cells which were inhibited after cotreatment with thiol antioxidants (Fig. 4). A recent study in
prostate cancer cells also linked the pro-apoptotic activity of CDDO-Me to induction of ROS (Deeb et al., 2010). Since induction of ROS and ROS-dependent responses play an important role in the anticancer activity of mitochondriotoxic anticancer drugs such as arsenic trioxide (Miller, Jr. et al., 2002), we hypothesized that repression of Sp transcription factors may be an ROS-dependent response. Results in Figure 4D show that CDDO-Me-dependent downregulation of Sp1, Sp3 and Sp4 proteins is significantly inhibited in Panc1 and L3.6pL cells after cotreatment with GSH and DTT. Moreover, using hydrogen peroxide and t-butyl hydroperoxide as prototypical ROS, both oxidants also decreased expression of Sp1, Sp3 and Sp proteins in pancreatic cancer cells (data not shown). These results demonstrate that the effects of CDDO-Me on mitochondria are linked to ROS-dependent downregulation of Sp1, Sp3 and Sp4 and we have also observed similar effects with arsenic trioxide in pancreatic cancer cells (Miller, Jr. et al., 2002).

The role of miR-27a and its suppression of the zinc finger protein ZBTB10 in regulating expression of Sp1, Sp3 and Sp4 has previously been characterized in breast and colon cancer cells (Abdelrahim et al., 2006; Mertens-Talcott et al., 2007). Both antisense miR-27a and ZBTB10 overexpression decrease Sp and Sp-dependent genes in these cell lines (Abdelrahim et al., 2006; Mertens-Talcott et al., 2007) and this is related to the effects of ZBTB10 which binds GC-rich sites and acts as an transcriptional repressor (Tillotson, 1999). Treatment of Panc1 and L3.6pL cells with CDDO-Me decreased expression of miR-27a (Fig. 5A) and this was accompanied by induction of ZBTB10 (Fig. 5B). These results are comparable to those observed for the structurally-related triterpenoid CDODA-Me in colon cancer cells (Abdelrahim et al., 2006; Mertens-
Talcott et al., 2007). We also confirmed that ZBTB10 overexpression in Panc1 and L3.6pL cells decreased levels Sp1, Sp3 and Sp4 proteins (Fig. 5C) as observed in colon and breast cancer cells (Abdelrahim et al., 2006; Mertens-Talcott et al., 2007). These studies also demonstrate for the first time that CDDO-Me-dependent induction of ROS is critical for downstream events since antioxidants inhibit downregulation of miR-27a, induction of ZBTB10 (Fig. 5D), and repression of Sp1, Sp3 and Sp4 (Fig. 4D) in Panc1 and L3.6pL cells treated with CDDO-Me. Since the downstream effects of CDDO-Me are associated with decreased expression of as-miR-27a which results in induction of ZBTB10 and downregulation of Sp1, Sp3 and Sp4, we also investigated the growth inhibitory/proapoptotic effects of individual steps in this pathway. Transfection of Panc1 and L3.6pL cells with as-miR-27a or ZBTB10 expression plasmid or a cocktail of small inhibitory RNAs against Sp1, Sp3 and Sp4 (iSp1/3/4) inhibited cell growth and induced PARP cleavage. There were some cell context-dependent differences in the effects of individual Sp knockdown; however, these results indicate that CDDO-Me-dependent perturbation of the miR-27a:ZBTB10–Sp1/3/4 axis contributes to the growth inhibitory and proapoptotic effects of CDDO-Me.

In summary, we have shown that CDDO-Me is highly cytotoxic to pancreatic cancer cells and tumors and this is consistent with previous reports on the potent anticancer activity of CDDO and related compounds (Honda et al., 1998; Honda et al., 2000; Ikeda et al., 2003; Ikeda et al., 2004; Liby et al., 2007; Melichar et al., 2004; Ray et al., 2006; Samudio et al., 2005; Samudio et al., 2006; Wang et al., 2000; Yore et al., 2006; Yue et al., 2006). Our results demonstrate for the first time that CDDO and CDDO-Me induce downregulation of Sp1, Sp3 and Sp4 transcription factors as well as
several Sp-dependent genes that are associated with cancer cell survival, growth and angiogenesis. These observations suggest that this pathway contributes to the potent antitumorigenic activity of CDDO and related compounds and may also explain, in part, the broad spectrum of activities of these drugs in cancer cell lines. CDDO-Me, like its imidazole derivative (Samudio et al., 2005), also induces ROS and decreases MMP in pancreatic cancer cells. We show that the induction of ROS leads to a cascade of events in which miR-27a is decreased and this is accompanied by induction of ZBTB10, a suppressor of Sp transcription factors and Sp-dependent genes (Abdelrahim et al., 2006; Mertens-Talcott et al., 2007; Tillotson, 1999). Activation of the ROS-miR-27a:ZBTB10–Sp axis by CDDO-Me represents a novel and highly practical route for targeting several Sp-regulated genes that play an important role in carcinogenesis. Current research is focused on improving the efficacy of drugs that target Sp transcription factors and also determining the specific ROS-induced factors and other pathways that lead to downregulation of miR-27a and other miRs that regulate potential Sp-repressor genes.
REFERENCES


FOOTNOTES

Funding: The financial assistance of the National Institutes of Health [R01CA108718, P20CA10193 and R01CA136571] and Texas A&M AgriLife Research is gratefully acknowledged.

* Both authors contributed equally.
FIGURE CAPTIONS

Figure 1. CDDO and CDDO-Me inhibit cell growth and induce apoptosis in pancreatic cancer cell lines. Inhibition of Panc1, Panc28 and L3.6pL cell growth by CDDO (A) and CDDO-Me (B). Cells were treated with DMSO (solvent control), CDDO (0.5, 1.0 or 2.5 μmol/L), or CDDO-Me (0.01, 0.1, 0.5 or 1.0 μmol/L), and effects on cell growth were determined over a period of 6 days as described in the Materials and Methods. Induction of PARP cleavage by CDDO (C) and CDDO-Me (D). Panc1, Panc28 and L3.6pL cells were treated with DMSO, CDDO (1.0, 2.5 or 5.0 μmol/L), or CDDO-Me (0.5, 1.0 or 1.25 μmol/L) for 24 hr, and whole-cell lysates were analyzed by western blot analysis as described in Materials and Methods. β-Actin served as a loading control.

Figure 2. CDDO and CDDO-Me decrease expression of VEGF, VEGFR2, cyclin D1 (CD1) and survivin proteins in Panc1 (A), Panc28 (B) and L3.6pL (C) pancreatic cancer cell lines. Cells were treated with DMSO, CDDO (1.0, 2.5 or 5.0 μmol/L), or CDDO-Me (0.5, 1.0 or 1.25 μmol/L) for 24 hr, and whole-cell lysates were analyzed by western blot analysis as described in Materials and Methods. β-Actin served as a loading control. The gels were typical of results of at least two replicate determinations per treatment group.

Figure 3. CDDO-Me downregulates Sp proteins in a proteosome-independent manner. CDDO-Me decreases Sp protein expression in Panc1 (A), Panc28 (B), and L3.6pL (C). Cells were with DMSO, CDDO (1.0, 2.5 or 5.0 μM), or CDDO-Me (0.5, 1.0 or 1.25 μM) for 24 hr, and whole-cell lysates were analyzed for Sp1, Sp3 and Sp4 by western blot analysis as described in Materials and Methods. D.
Proteosome-independent downregulation of Sp proteins by CDDO-Me. Cells were treated with DMSO and CDDO-Me (1.0 μmol/L) in the presence or absence of proteasome inhibitor MG132 (10 μM), and the effects on Sp protein degradation were determined after treatment for 24 hr by western blot as described in Materials and Methods. β-Actin served as a loading control.

**Figure 4.** Role of oxidative stress and mitochondrial membrane potential (MMP) in mediating the effects of CDDO-Me on Sp proteins in pancreatic cancer cells. Effect of CDDO-Me on ROS (A) and MMP (B, C). Panc1 and L3.6pL cells were treated with DMSO and CDDO-Me (0.5, 1.0 or 1.25 μmol/L) for 24 hr in the presence or absence of antioxidant GSH. ROS was measured using BioTek Synergy 4 plate reader using CM-H$_2$DCFDA (10 μM) dye as described in Materials and Methods, and normalized fluorescence intensity against control is plotted as a bar diagram. MMP was determined using JC-1 dye and quantitation of the ratio of red to green fluorescence was measured using Image J Software as described in Materials and Methods. D. Reversal of CDDO-Me-mediated downregulation of Sp proteins by thiol antioxidants. Cells were treated with DMSO or CDDO-Me (1.0 μmol/L) in the presence or absence of DTT or GSH for 24 hr, and whole cell lysates were analyzed by western blots as described in Materials and Methods. β-Actin served as a loading control. Results in A and C are expressed as means ± SE for three replicate determinations for each treatment group, and significant (P < 0.05) CDDO-Me-mediated decreases (*) or increases (**) after cotreatment with antioxidants compared to the solvent (DMSO) control are indicated.
Figure 5. Effect of CDDO-Me on expression miR-27a and ZBTB10 mRNA and role of ZBTB10 overexpression on Sp proteins in pancreatic cancer cells. CDDO-Me decreases miR-27a (A) and induces ZBTB10 mRNA (B). Panc1 and L3.6pL cells were treated with the indicated doses of CDDO-Me for 24 hr, and miR-27a and ZBTB10 levels were analyzed by real time PCR as described in Materials and Methods. C. Effect of ZBTB10 overexpression on Sp proteins and Sp-dependent genes. Panc1 and L3.6pL cells were transfected with empty vector (pCMV6-XL4) or 4 μg/well ZBTB10 expression plasmid pCMV6-XL4 vector, and whole cell lysates were analyzed by western blots as described in Materials and Methods. D. Effect of GSH on CDDO-Me-mediated miR-27a and ZBTB10 mRNA expression. Panc1 and L3.6pL cells were treated with indicated doses of CDDO-Me in the presence or absence of GSH for 24 hr, and miR-27a and ZBTB10 mRNA levels were analyzed by real time PCR as described in Materials and Methods. Results in A, B and D are expressed as means ± SE for three replicate determinations for each treatment group and significant (*P < 0.05) inhibition (•) or induction (★★) of responses are indicated.

Figure 6. Growth inhibition and induction of apoptosis by as-miR-27a, ZBTB10 and Sp knockdown. Panc1 and L3.6pL cells were transfected with as-miR-27a (A), ZBTB10 expression plasmid (B), and small inhibitory RNAs against Sp transcription factors (C and D), and their effects on cell proliferation and induction of PARP cleavage were determined as described in the Materials and Methods. Western blots are typical of at least 2 replicate determinations. Cell numbers are given as means ± SE of 3 replicate determinations. Significant (*P < 0.05) growth
inhibition is indicated (*). RNA interference decreased expression of individual Sp proteins approximately 60-80% as described (Chadalapaka et al., 2008a; Chadalapaka et al., 2010).

Figure 7. CDDO-Me inhibits pancreatic tumor growth and downregulates Sp proteins and Sp dependent genes. Tumor weights (A) and volume (B). Male athymic nude mice bearing orthotopic pancreatic (L3.6pL) tumors were treated with corn oil or CDDO-Me (7.5 mg/Kg) for 4 weeks and tumor weights and tumor volumes (mm$^3$) were determined as described in Materials and Methods. Significant ($P < 0.05$) inhibition (*) is indicated in results as means ± SE for five animals per treatment. Western blot analysis of tumor lysates for Sp proteins (C) and Sp-dependent proteins (D). Lysates from three mice in the treated and control groups were analyzed by western blots as described in Materials and Methods. β-Actin served as loading control.
Figure 2

A

<table>
<thead>
<tr>
<th>CDOD-Me (μmol/L)</th>
<th>0</th>
<th>0.5</th>
<th>1</th>
<th>2.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Panc1

<table>
<thead>
<tr>
<th>CDOD (μmol/L)</th>
<th>0</th>
<th>1</th>
<th>2.5</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>CDOD-Me (μmol/L)</th>
<th>0</th>
<th>0.5</th>
<th>1</th>
<th>2.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Panc28

<table>
<thead>
<tr>
<th>CDOD (μmol/L)</th>
<th>0</th>
<th>1</th>
<th>2.5</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th>CDOD-Me (μmol/L)</th>
<th>0</th>
<th>0.5</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

L3.6pL

<table>
<thead>
<tr>
<th>CDOD (μmol/L)</th>
<th>0</th>
<th>2.5</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 5

A. miR-27a levels in Panc1 and L3.6pL cells treated with CDDO-Me at different concentrations.

B. ZBTB10 levels in Panc1 and L3.6pL cells treated with CDDO-Me at different concentrations.

C. Western blot analysis of Sp1, Sp3, Sp4, and Cyclin D1 expression in Panc1 and L3.6pL cells treated with ZBTB10 (μg) 0 and 4.

D. Relative miR-27a and ZBTB10 mRNA levels in Panc1 and L3.6pL cells treated with CDDO-Me, GSH (5 mM), and +GSH.
Figure 7

A

B

C

D

Molecular Pharmacology Fast Forward. Published on May 20, 2010 as DOI: 10.1124/mol.110.064451

Downloaded from molpharm.aspetjournals.org at ASPET Journals on July 6, 2017.
**Supplemental Figure 1.** Growth inhibitory effects of CDDO-Me. Panc1, Panc28, L3.6pL and HPDE (non-transformed) cells were treated with different concentrations of CDDO-Me for 48 hr, and cells were counted as described in the Materials and Methods. Results are expressed as means ± SE for 3 replicate determinations for each treatment group, and significant ($P < 0.05$) decreases in cell proliferation are indicated (*).
Supplemental Figure 2. CDDO and CDDO-Me decrease transactivation of Sp1, Sp3, VEGF and survivin promoter constructs. Panc1 cells were treated with DMSO (solvent control), CDDO-Me (0.5, 1.0 or 1.25 μmol/L), or CDDO (2.5 or 5.0 μmol/L) and effects on transactivation of promoters were determined after treatment for 24 hr as described in Materials and Methods. Results are expressed as means ± SE for three replicate determinations for each treatment group, and significant (P < 0.05) decreases in luciferase activity compared to the solvent (DMSO) control are indicated (*).
Supplemental Figure 3. Effect of CDDO-Me on Sp1 mRNA levels. Panc-1 cells were treated with DMSO or CDDO-Me (1.0 or 1.25 μmol/L) for 24 hr and Sp1 mRNA levels were analyzed using real time PCR as described in Materials and Methods.